Dr. Nomita Kim Co-Authors Positive MASH Trial Results Published in The Lancet
We’re proud to share that one of our clinical research sites played a key role in a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH)—a serious, progressive liver disease affecting millions of people worldwide. The trial demonstrated positive results for patients, representing a significant step forward in the development of treatment options for MASH.
The findings were recently published in The Lancet, a respected peer-reviewed medical journal. This publication represents an important milestone not just for the clinical trial community, but also for patients, families, and care providers seeking real progress in the treatment of liver disease.
A standout contributor to the success of this trial was Dr. Nomita Kim, who served as the Principal Investigator at the IMA Clinical Research site in Austin, TX. Dr. Kim brought her deep clinical expertise and unwavering commitment to excellence throughout the study—from protocol implementation to patient oversight and data quality- helping to ensure the site’s successful execution of the trial while upholding the highest standards of patient care and research integrity.
Dr. Kim also served as a co-author on the publication in The Lancet, reflecting not only her hands-on role in the trial but also her contribution to the broader scientific conversation.
We congratulate Dr. Kim on this well-earned recognition!
For detailed findings check out Dr. Kim’s co-authored article in The Lancet:
Efimosfermin in participants with phenotypic metabolic dysfunction-associated steatohepatitis
